Company News 

Is bruised Vectura ready for recovery?

Is bruised Vectura ready for recovery?

Vectura’s (VEC) annual results provide plenty of ammunition for both bulls and bears. On the plus side, underlying revenues – after adjusting for the 2016 merger with peer Skyepharma – rose 4 per cent to £131m, but throw in non-recurring milestone payments for partnered drug programmes, and the group’s pro-forma revenue dropped to £184m. Meanwhile, a non-cash impairment of £110m widened Vectura’s operating loss position. But strip that (and the non-recurring revenues) out and adjusted cash profit rose to £10m thanks to significant cost savings from merger synergies.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now